2. Stage III (T1-4, N1-2, M0) colorectal cancer patients.
3. Patients who can undergo R0 resection.
4. ECOG score 0 \~ 2.
5. Expected survival ≥ 6 months.
6. No history of other malignant tumors.
7. Voluntarily participate in this study and sign the informed consent. If the subject does not have the ability to read the informed consent (e.g., illiterate subjects), a witness must witness the informed process and sign the informed consent.
You may not be if
1. Patients who have received neoadjuvant chemotherapy.
2. Known high clinical risk of adjuvant chemotherapy.
3. Patients with clear contraindications to adjuvant chemotherapy (i.e. due to physical condition, comorbidities, active second cancer, or age).
4. Patients who are unable to undergo subsequent chemotherapy due to other reasons (travel distance, compliance).
5. Vulnerable groups, including people with mental illness, people with cognitive impairment, critically ill patients, minors, pregnant women, etc.
6. There are any other circumstances that the researcher deems unsuitable for inclusion.
